Vivera BioSciences is focused on developing a selection of non-addictive drugs for indications including cardiovascular conditions and central nervous system and fluency disorders. The division pipeline centers around the utilization of TABMELT,  a novel patented and patent-pending sublingual drug delivery system that allows patients to take a medication by simply dissolving a tablet under their tongue. This delivery route may lead to more instantaneous and accurate absorption than that of oral drug delivery.

Visit to learn more.